UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 150

Sortiert nach

Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Clinical cancer research, 2019-05, Vol.25 (10), p.3046-3053

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1619-1625

2008

Link zum Volltext

Verfügbarkeit prüfen

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS4124-TPS4124

2020

Link zum Volltext

Verfügbarkeit prüfen

International harmonization of diagnostic criteria for HER2 -amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3594-3594

2018

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3508-3508

2015

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3636-3636

2013

Link zum Volltext

Verfügbarkeit prüfen

Time course of regorafenib-associated adverse events in the phase III CORRECT study

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.467-467

2013

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9141-TPS9141

2022

Link zum Volltext

Verfügbarkeit prüfen

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2023-06, Vol.41 (18), p.3278-3286

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA3000-LBA3000

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3636-TPS3636

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.127-127

2022

Link zum Volltext

Verfügbarkeit prüfen

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3513-3513

2023

Link zum Volltext

Verfügbarkeit prüfen

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3631-TPS3631

2023

Link zum Volltext

Verfügbarkeit prüfen

Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3633-TPS3633

2023

Link zum Volltext

Verfügbarkeit prüfen

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS261-TPS261

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to E. Hawkes et al

Journal of clinical oncology, 2010-10, Vol.28 (28), p.e532-e533

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3506-3506

2021

Link zum Volltext

Verfügbarkeit prüfen

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2466-2476

2020

Link zum Volltext

Verfügbarkeit prüfen

Genomic landscape of ERBB2/3 alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.176-176

2022

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS224-TPS224

2022

Link zum Volltext

Verfügbarkeit prüfen

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3528-3528

2023

Link zum Volltext

Verfügbarkeit prüfen

High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS2675-TPS2675

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 150

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaHumans

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(146)

Publikationsform

Artikel
(149)
Tagungsberichte
(1)

Sprache

Englisch
(150)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Oncology
(11)
Cancer Research
(7)
Life Sciences & Biomedicine
(6)
Physical Sciences
(4)
Physics
(4)
Biological And Medical Sciences
(2)
Cancer
(2)
Colorectal Cancer
(2)
Genetic Aspects
(2)
Health Aspects
(2)
Immunotherapy
(2)
Medical Sciences
(2)
Multidisciplinary Sciences
(2)
Science & Technology - Other Topics
(2)
Tumors
(2)
645400 - High Energy Physics- Field Theory
(1)
Accelerators
(1)
Allogeneic Blood Stem Cell Transplantation
(1)
Analysis
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

International harmonization of diagnostic criteria for HER2 -amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial

Time course of regorafenib-associated adverse events in the phase III CORRECT study

A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results

Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study

Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer

Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial)

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress

Reply to E. Hawkes et al

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Genomic landscape of ERBB2/3 alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02)

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS

High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study

Aktive Filter

Suchergebnisse filtern